Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development

Bio-Techne Corporation (NASDAQ:TECH) is one of the best S&P 500 stocks with huge upside potential. On June 24, Bio-Techne Corporation announced a distribution agreement with the US Pharmacopeia/USP. The collaboration allows Bio-Techne to sell USP monoclonal antibody/mAb and recombinant adeno-associated virus/AAV reference standards alongside its analytical solutions, like the Maurice system, to support the global development of monoclonal antibody and gene therapy products.

Over 160 antibody therapies targeting ~100 diseases have been approved worldwide. The expiration of mAb patent protections and the emergence of biosimilar versions further emphasize the need for rigorous testing of critical quality attributes throughout the development and manufacturing processes for product safety and efficacy.

Bio-Techne, USP Partner to Enhance Monoclonal Antibody, Gene Therapy Development

A team of scientists wearing lab coats and protective eyewear in a research laboratory, intently looking into microscopes and analyzing results.

The USP mAb and AAV reference standards are compatible with Bio-Techne’s analytical instruments, such as the MauriceFlex system. By combining these standards with Bio-Techne’s rapid, user-friendly, and multi-functional analytics, therapy manufacturers can achieve reliable, efficient, and integrated characterization for purity, charge, size, and identity applications for complex biologics, from the initial development phases through to product release.

Bio-Techne Corporation (NASDAQ:TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.

While we acknowledge the potential of TECH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.